Amendments to the Claims:

This listing of claims replaces all prior versions, and listings, of claims in the application:

1. (Currently amended) A chimeric polypeptide, said chimeric polypeptide comprising:

   a) a first domain ~~comprising~~ consisting essentially of ~~an~~ third intracellular loop (i3 loop) or a fragment thereof ~~portion~~ of a G protein coupled receptor (GPCR), and

   b) ~~at least~~ a second domain, attached to the first domain, wherein said second domain is a naturally or non-naturally occurring cell-penetrating, membrane-tethering hydrophobic moiety

   wherein said first domain does not comprise a native extracellular portion of said GPCR and wherein said chimeric polypeptide binds to its cognate GPCR.

2. (currently amended) The chimeric polypeptide of claim 1, wherein said ~~second or more domains are~~ hydrophobic moiety is attached at ~~either one end, at both ends, or at an internal position~~ the N-terminal end, the C-terminal end, or both the N-terminal and C-terminal ends of said first domain.

3. (previously amended) The chimeric polypeptide of claim 1, wherein said hydrophobic moiety is a lipid.

4. (amended herein) The chimeric polypeptide of claim 3, wherein said hydrophobic moiety is selected from the group consisting of: capryloyl (C_8); nonanoyl (C_9); capryl (C_{10}); undecanoyl (C_{11}); lauroyl (C_{12}); tridecanoyl (C_{13}); myristoyl (C_{14}); pentadecanoyl (C_{15}); palmitoyl (C_{16}); phtanoyl ($(CH_3)_4$); heptadecanoyl (C_{17}); and stearoyl (C_{18}), ~~stearoyl (C18), palmitoyl (C16), myristoyl (C14), lauryl (C12), capryl (C10), and capryloyl (C8)~~ wherein said hydrophobic moiety is attached to said chimeric polypeptide with amide bonds, sulfhydryls, amines, alcohols, phenolic groups, or carbon-carbon bonds.

5. Cancelled.

6. - 9. Cancelled.

10. (currently amended) The chimeric polypeptide of claim ~~6~~ 1, where said ~~intracellular portion is~~ i3 loop or fragment thereof comprises at least 3 contiguous amino acid residues of the third intracellular loop.

~~11.~~ 6 (currently amended) The chimeric polypeptide of claim ~~6~~ 1, wherein said is at least 5 ~~intracellular portion is~~ i3 loop or fragment thereof comprises at least 5 contiguous amino acid residues of the third intracellular loop.

12. (canceled)

~~13.~~ 7 (currently amended) The chimeric polypeptide of claim ~~12~~ 1, wherein said ~~intracellular portion~~ i3 loop or fragment thereof comprises at least 7 contiguous amino acid residues of the third intracellular loop.

~~14.~~ 8 (Currently amended) The chimeric polypeptide of claim 1, wherein said first domain comprises a protease-activated receptor (PAR) and said second domain comprises a lipid moiety.

15. Cancelled.

16. Cancelled.

17. Cancelled.

18. Cancelled.

~~19.~~ 9 (amended herein) The chimeric polypeptide of claim 1, wherein the G-protein coupled receptor or fragment thereof, is selected from the group consisting of a luteinizing hormone receptor, a follicle stimulating hormone receptor, a thyroid stimulating hormone receptor, a calcitonin receptor, a glucagon receptor, a glucagon-like peptide 1 receptor (GLP-1), a metabotropic glutamate receptor, a parathyroid hormone receptor, a vasoactive intestinal peptide receptor, a secretin receptor, a growth hormone releasing factor (GRF) receptor, protease-activated receptors (PARs), cholecystokinin receptors, somatostatin receptors, melanocortin receptors, ADP receptors, adenosine receptors, thromboxane receptors, platelet activating factor receptor, adrenergic receptors, 5-HT receptors, CXCR4, CCR5, chemokine receptors, neuropeptide receptors, opioid receptors, ~~erythropoietin receptor, von Willebrand receptor,~~ parathyroid hormone (PTH) receptor, and vasoactive intestinal peptide (VIP) receptor~~, and collagen receptors~~.

20. – 28. Cancelled.

~~29.~~ 10 (Original) A pharmaceutical composition comprising the chimeric polypeptide of claim 1 and a pharmaceutically acceptable carrier.

30. Cancelled.

~~31.~~ 11 (Original) A kit comprising in one or more containers, the pharmaceutical composition of claim ~~29.~~ 10

32.- 34. Cancelled.

~~35.~~ 12 (Previously added) The chimeric polypeptide of claim 1, wherein said G-protein coupled receptor is a mammalian G-protein coupled receptor.

~~36.~~ 13 (Previously added) The chimeric polypeptide of claim 4, wherein said hydrophobic moiety is palmitoyl.

~~37.~~ 14 (Previously added) The chimeric polypeptide of claim ~~19~~ 1, wherein said G-protein coupled receptor is a protease-activated receptor (PAR).

~~38.~~ 15 (Previously added) The chimeric polypeptide of claim ~~37~~ 14, wherein the protease-activated receptor is selected from the group consisting of PAR1, PAR2, and PAR4.

~~39.~~ 16 (Previously added) The chimeric polypeptide of claim ~~12~~ 1, wherein said ~~intracellular portion~~ i3 loop or fragment thereof comprises a sequence selected from the group consisting of SEQ ID NO: 1-16, 19-23, and 29.

~~40.~~ 17 (currently amended) The chimeric polypeptide of claim ~~12~~ 1, wherein said ~~intracellular portion~~ i3 loop or fragment therof comprises a sequence selected from the group consisting of SEQ ID NO: 1-10, and 23.

~~41.~~ 18 (Previously added) The chimeric polypeptide of claim 1, wherein the said G-protein coupled receptor is selected from the group consisting of CCKA, CCKB, SSTR2, and SubP receptors.

~~42.~~ 19 (Previously added) The chimeric polypeptide of claim 3, wherein said hydrophobic moiety is a steroid.

~~43.~~ 20 (currently amended) A chimeric polypeptide, said chimeric polypeptide comprising:

a) a first domain comprising an ~~intracellular portion~~ isolated i3 loop or fragment thereof of a protease-activated receptor (PAR), and

b) a second domain, attached to the first domain, wherein said second domain is palmitate.

~~44.~~ 21 (new) The chimeric polypeptide of claim 1, wherein said hydrophobic moiety is selected from the group consisting of a phospholipid, a steroid, a sphingosine, a ceramide, an octyl-glycine, a 2-cyclohexylalanine, and a benzolylphenylalanine.

~~45.~~ 22 (new) The chimeric polypeptide of claim 1, further comprising a third domain, said third domain being a cell-penetrating, membrane tethering hydrophobic moiety attached to said first domain.

~~46.~~ 23 (new) The chimeric polypeptide of claim 1, wherein said i3 loop or fragment thereof comprises the amino acid sequence of SEQ ID NO:1.

~~47.~~ 24 (new) The chimeric polypeptide of claim 1, wherein said i3 loop or fragment thereof comprises the amino acid sequence of SEQ ID NO:2.

~~48.~~ 25 (new) The chimeric polypeptide of claim 1, wherein said i3 loop or fragment thereof comprises the amino acid sequence of SEQ ID NO:3.

~~49.~~ 26 (new) The chimeric polypeptide of claim 1, wherein said i3 loop or fragment thereof comprises the amino acid sequence of SEQ ID NO:4.

~~50.~~ 27 (new) The chimeric polypeptide of claim 1, wherein said i3 loop or fragment thereof comprises the amino acid sequence of SEQ ID NO:5.

~~51.~~ 28 (new) The chimeric polypeptide of claim 1, wherein said i3 loop or fragment thereof comprises the amino acid sequence of SEQ ID NO:6.

~~52.~~ 29 (new) The chimeric polypeptide of claim 1, wherein said i3 loop or fragment thereof comprises the amino acid sequence of SEQ ID NO:7.

~~53.~~ 30 (new) The chimeric polypeptide of claim 1, wherein said i3 loop or fragment thereof comprises the amino acid sequence of SEQ ID NO:8.

~~54.~~ 31 (new) The chimeric polypeptide of claim 1, wherein said i3 loop or fragment thereof comprises the amino acid sequence of SEQ ID NO:9.

~~55.~~ 32 (new) The chimeric polypeptide of claim 1, wherein said i3 loop or fragment thereof comprises the amino acid sequence of SEQ ID NO:10.

~~56.~~ 33 (new) The chimeric polypeptide of claim 1, wherein said i3 loop or fragment thereof comprises the amino acid sequence of SEQ ID NO:11.

~~57.~~ 34 (new) The chimeric polypeptide of claim 1, wherein said i3 loop or fragment thereof comprises the amino acid sequence of SEQ ID NO:12.

~~58.~~ 35 (new) The chimeric polypeptide of claim 1, wherein said i3 loop or fragment thereof comprises the amino acid sequence of SEQ ID NO:13.

~~59.~~ 36 (new) The chimeric polypeptide of claim 1, wherein said i3 loop or fragment thereof comprises the amino acid sequence of SEQ ID NO:14.

~~60.~~ 37 (new) The chimeric polypeptide of claim 1, wherein said i3 loop or fragment thereof comprises the amino acid sequence of SEQ ID NO:15.

~~61.~~ 38 (new) The chimeric polypeptide of claim 1, wherein said i3 loop or fragment thereof comprises the amino acid sequence of SEQ ID NO:16.

~~62.~~ 39 (new) The chimeric polypeptide of claim 1, wherein said i3 loop or fragment thereof comprises the amino acid sequence of SEQ ID NO:19.

~~63.~~ 40 (new) The chimeric polypeptide of claim 1, wherein said i3 loop or fragment thereof comprises the amino acid sequence of SEQ ID NO:20.

~~64.~~ 41 (new) The chimeric polypeptide of claim 1, wherein said i3 loop or fragment thereof comprises the amino acid sequence of SEQ ID NO:21.

~~65.~~ 42 (new) The chimeric polypeptide of claim 1, wherein said i3 loop or fragment thereof comprises the amino acid sequence of SEQ ID NO:22.

~~66.~~ 43 (new) The chimeric polypeptide of claim 1, wherein said i3 loop or fragment thereof comprises the amino acid sequence of SEQ ID NO:23.

~~67.~~ 44 (new) The chimeric polypeptide of claim 1, wherein said i3 loop or fragment thereof comprises the amino acid sequence of SEQ ID NO:28.

~~68.~~ 45 (new) The chimeric polypeptide of claim 1, wherein said i3 loop or fragment thereof comprises the amino acid sequence of SEQ ID NO:29.

~~69.~~ 46 (new) The chimeric polypeptide of claim 1, wherein the hydrophobic moiety is a steroid.